Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 259

Posts Tagged ‘dendreon’

Dendreon Publishes New Data in Clinical Cancer Research

Posted by fidest press agency su martedì, 5 giugno 2018

Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced publication of new data in Clinical Cancer Research, a journal of the American Association for Cancer Research, showing that treatment with PROVENGE® (sipuleucel-T) generates killer T cells that target prostatic acid phosphatase (PAP), a protein expressed on the majority of prostate cancer cells. The results of this analysis provide further evidence around the relationship between killer T cell activity and overall survival in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC).“This research suggests the role of sipuleucel-T in the generation of killer T cells following treatment,” said Charles G. Drake, M.D., Ph.D., director of genitourinary oncology at Columbia University Medical Center and senior author. “Importantly, these data suggest how the mechanism of action of sipuleucel-T may, in part, translate into survival benefit for patients.”To quantify potential cytotoxic T lymphocyte (CTL) activity, cell-surface CD107a expression on PAP-specific CD8+ T cells was measured in samples from a subset of patients enrolled in Dendreon’s STAMP clinical trial (study ID: P11-3) before and after sipuleucel-T treatment. It was observed that T cells were able to recognize and target PAP only after sipuleucel-T treatment, with responses observed at 6 weeks and sustained out to 26 weeks post-treatment. Importantly, the magnitude of the CTL activity at week 26 correlated with increased overall survival, indicating that PROVENGE evokes a memory T cell response that may play a role in the survival benefit of PROVENGE.“While the IMPACT trial established the survival benefit of sipuleucel-T, the mechanism of action of treatment has not been fully appreciated,” said Bruce A. Brown, M.D., senior vice president, medical, at Dendreon. “This research provides more information about how sipuleucel-T works and – for the first time – correlates the magnitude of killer T cell activity with overall survival.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »